Our mission at D3 Bio is to build a global biotechnology company that develops innovative and more efficacious medicines for patients in need worldwide.
George Chen, MD
About D3 Bio
D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – where existing standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into lab to guide the identification of fit for purpose science and technology, and define our drug development path.
D3 Bio R&D programs are also designed to create a structure, which would enable us to create a robust portfolio and identify assets carrying “back-bone” property for developing future therapies in multiple indications. Our portfolio will include assets from internal effort as well as assets in-licensed in pre-clinical or clinical-stage investigational compounds. This cycle of innovation is at the heart of D3 Bio. In fact, it underlies our name: Development leading to Discovery that then leads back to more Development, or D3 Bio.”
D3 Bio is backed by a syndicate of world-class investors whose support underscores their belief in the promise of the Company. Major investors include Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund.
D3 Bio is to transform the lives of patients worldwide who suffer from the most difficult-to-treat, life threatening or debilitating conditions. Creating break-through precision medicines that match therapies to the disease biomarkers of individual patients, D3 Bio is committed to convert life-threatening cancers into manageable chronic conditions. We envision D3 Bio’s novel therapeutics would satisfy the unmet needs of cancer patients across the globe.
D3 Bio brings a level of world-class experience at multinational big pharma companies that promises success for the Company’s visionary approach to drug discovery, development and commercialization. With strong track records in successfully introducing major drugs into the U.S., Chinese and other markets, the D3 Bio team understands the science and market requirements for translational drug development. Their unique vision for D3 Bio is to create a bridge between insights about the actual clinical needs of patients and the scientific, biomarker-driven research needed to create precision medicines for the world.
George Chen, MD
Co-Founder, Chairman, & CEO
George Chen is an oncologist by training with a successful track record in the world of global pharmaceutical companies. Prior to founding D3 Bio, Dr. Chen held senior global positions in research, drug development and management at leading institutions, such as the National Institutes of Health, and multinational pharmaceutical companies, such as Eli Lilly, GlaxoSmithKline, Johnson & Johnson and Astra Zeneca. At these organizations he led development and regulatory registrations of blockbuster drugs into the U.S. and Chinese markets, directing more than 70 IND approvals and more than 30 NDAs. His medical degree is from the Shanghai Medical College of Fudan University and his MBA is from the Wharton School of Business at the University of Pennsylvania.
John Jin, PHD
Co-Founder, CFO, CBO, & Board Member
John Jin was previously a founding partner at Hanne Capital and former VP of Business Development both at BeiGene and at TaiGen Biotechnology (Taiwan). Dr. Jin had been responsible for venture investment, corporate and business development, government affairs, and global cross-border licensing deals for cancer and other drugs within China and internationally. During his early career, Dr. Jin took on various managerial roles at Clearview Projects, a US boutique strategic advisory firm, Eli Lilly and Millennium Pharmaceuticals. Dr. Jin has more than 20 years of experience in cross-border investment and financing, pharmaceutical business development and drug licensing, and research and development. Dr. Jin has a Bachelor of Medicine from Peking University School of Medicine, an MBA from Wharton School of Business at the University of Pennsylvania and a Ph.D. in Immunology from Cornell University School of Medicine.
D3Bio has built a pipeline of multiple pre-clinical stage oncology programs, all of which have first-in-class or best-in-class potential and carry foundational properties targeting immune-pathways or tumor driving mutations. D3 Bio owns global rights to all the programs.